Biopharmaceutical Company
Appears in 1 story
FDA approval received for once-weekly YUVIWEL; launch planned early Q2 2026
About 250,000 people worldwide have achondroplasia, the most common genetic cause of dwarfism. Until BioMarin's Voxzogo, the only approved treatment required daily injections.
Updated May 29
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
